Applied Therapeutics - APLT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.05
  • Forecasted Upside: 1,084.86 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.93
▼ -0.02 (-2.10%)

This chart shows the closing price for APLT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Applied Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APLT

Analyst Price Target is $11.05
▲ +1,084.86% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Applied Therapeutics in the last 3 months. The average price target is $11.05, with a high forecast of $23.00 and a low forecast of $2.25. The average price target represents a 1,084.86% upside from the last price of $0.93.

This chart shows the closing price for APLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Applied Therapeutics. This rating has held steady since August 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2022CitigroupLower TargetBuy$29.00 ➝ $23.00Low
8/16/2022BarclaysLower TargetEqual Weight$2.50 ➝ $2.25Low
5/20/2022CitigroupLower TargetBuy$29.00High
4/13/2022Truist FinancialLower Target$6.00High
3/21/2022BarclaysLower TargetEqual Weight$7.00 ➝ $2.50High
1/5/2022CitigroupBoost TargetBuy ➝ Buy$30.00 ➝ $38.00High
1/4/2022The Goldman Sachs GroupLower Target$10.00 ➝ $3.00High
1/4/2022Robert W. BairdLower Target$35.00 ➝ $21.00Medium
1/4/2022BarclaysDowngradeOverweight ➝ Equal Weight$44.00 ➝ $7.00High
9/12/2021Robert W. BairdReiterated RatingBuy$35.00Medium
8/26/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$16.00 ➝ $10.00High
6/25/2021The Goldman Sachs GroupInitiated CoverageNeutral$18.00High
3/21/2021Robert W. BairdReiterated RatingBuy$35.00High
11/17/2020BarclaysLower Target$64.00 ➝ $44.00Low
10/8/2020Truist FinancialInitiated CoverageBuy$85.00 ➝ $85.00Low
6/17/2020CowenReiterated RatingBuyMedium
4/22/2020The Goldman Sachs GroupInitiated CoverageBuy$60.00Medium
3/3/2020CowenReiterated RatingBuyN/A
2/27/2020BarclaysInitiated CoverageOverweight$64.00 ➝ $64.00Low
1/27/2020UBS GroupBoost TargetBuy$65.00Medium
1/9/2020CitigroupBoost TargetBuy$29.00 ➝ $44.00High
1/8/2020CowenReiterated RatingBuyHigh
1/8/2020Robert W. BairdBoost TargetPositive ➝ Outperform$24.00 ➝ $43.00High
6/10/2019CitigroupInitiated CoverageBuy$29.00High
6/10/2019CowenInitiated CoverageOutperformHigh
6/10/2019UBS GroupInitiated CoverageBuyHigh
6/10/2019Robert W. BairdInitiated CoverageOutperform$24.00High
(Data available from 12/4/2017 forward)

News Sentiment Rating

1.58 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/8/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/4/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Applied Therapeutics logo
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $0.93
Low: $0.92
High: $1.00

50 Day Range

MA: $0.80
Low: $0.54
High: $1.12

52 Week Range

Now: $0.93
Low: $0.50
High: $11.44

Volume

66,654 shs

Average Volume

467,815 shs

Market Capitalization

$44.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Applied Therapeutics?

The following equities research analysts have issued reports on Applied Therapeutics in the last twelve months: Barclays PLC, Citigroup Inc., Robert W. Baird, The Goldman Sachs Group, Inc., and Truist Financial Co..
View the latest analyst ratings for APLT.

What is the current price target for Applied Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Applied Therapeutics in the last year. Their average twelve-month price target is $11.05, suggesting a possible upside of 1,084.9%. Citigroup Inc. has the highest price target set, predicting APLT will reach $23.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $2.25 for Applied Therapeutics in the next year.
View the latest price targets for APLT.

What is the current consensus analyst rating for Applied Therapeutics?

Applied Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APLT will outperform the market and that investors should add to their positions of Applied Therapeutics.
View the latest ratings for APLT.

What other companies compete with Applied Therapeutics?

How do I contact Applied Therapeutics' investor relations team?

Applied Therapeutics' physical mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company's listed phone number is (212) 220-9226 and its investor relations email address is [email protected] The official website for Applied Therapeutics is www.appliedtherapeutics.com. Learn More about contacing Applied Therapeutics investor relations.